Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Needham initiated coverage on Ocular Therapeutix Inc (NASDAQ:OCUL), noting the company’s lead asset, Axpaxli, an investigational axitinib-based intravitreal implant for wet age-related macular degeneration (wet AMD).
Axpaxli is the company’s key value driver and is under evaluation in two phase 3 trials. If positive, these trials could support approval with a product label that enables maintenance treatment with Q6M (every 6 months)-Q12M (every 12 months) dosing, which would represent a significant improvement over current treatment options that offer up to Q2M (every two months)-Q4M (every 4 months) dosing.
Also Read: Analyst Sees Wendy’s Playing Catch-Up, Needs Stronger Focus on Tech, Talent & Global Expansion
Ocular Therapeutix has completed randomization in the first wet AMD trial, SOL-1. The company expects topline results for SOL-1 to be available in the fourth quarter of 2025.
The company has enrolled 311 subjects in SOL-R, Ocular’s second registrational trial of Axpaxli in wet AMD. The company also plans to seek FDA feedback in the first half of 2025 on clinical trial design for Axpaxli in non-proliferative diabetic retinopathy (NPDR).
The analyst Serge Belanger has initiated with a Buy rating and a price target of $15.
Needham writes that intravitreally injected anti-VEGFs make up the ~$15 billion retinal disease market.
The analyst expects Axpaxli to play a role as a second-line treatment in the ~40% of 1.65 million wet AMD patients treated with anti-VEGFs who fail to adequately respond to anti-VEGFs and/or are dissatisfied with the high number of required IVT injections. Needham expects peak sales of around $1.5 billion based on a 15-20% share of this second-line AMD patient population.
“We believe Axpaxli’s product profile and unique pivotal ph 3 program offer substantial advantageous differentiation over other products in development seeking to provide long-term treatment duration,” Needham writes.
Ocular Therapeutix reported a fourth-quarter loss of 29 cents per share, compared to a consensus of 24 cents, with sales of $17.1 million.
The company expects its cash balance of $392.1 million to fund operations into 2028 without raising additional capital.
Price Action: OCUL stock is up 10.10% at $8.42 at the last check on Tuesday.
Read Next:
- Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes
Photo via Shutterstock
Latest Ratings for OCUL
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2022 | JMP Securities | Maintains | Market Outperform | |
| Nov 2021 | JMP Securities | Maintains | Market Outperform | |
| Oct 2021 | HC Wainwright & Co. | Maintains | Buy |
View More Analyst Ratings for OCUL
View the Latest Analyst Ratings
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
- OCULAR THERAPEUTIX (OCUL): Free Stock Analysis Report
This article Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available